Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Email Communication, February 2, 2010 AM - MenHibrix


Submission Type: BLA       Submission ID: 125363/0      Office: OVRR Product:
Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
GlaxoSmithKline Biologicals
Telecon Date/Time: 02-Feb-2010 12:00 AM           Initiated by FDA? Yes
Telephone Number: Communication Categorie(s):
1. Other - Request for column for testing
Author: CAMPBELL, KAREN Telecon Summary:
Request for qualified --------------------(b)(4)------------------------------------------------------------- for MenC-TT and MenY-TT conjugates in the final container vaccine
FDA Participants: Karen Campbell
Non-FDA Participants: Norris Pyle, GSK
Telecon Body: The following was provided to GSK via e-mail:
Dear Norris,
In the testing lab we are interested in receiving a qualified --------(b)(4)---------- supplied by                       ---(b)(4)----- used in performing the test for ------------(b)(4)------------------------------------ for MenC- TT and MenY-TT conjugates in the final container vaccine.
Please contact me if you have any questions. The column can be sent to:
Al Del Grosso
Center for Biologics Evaluation and Research
Nicholson Lane Research Center, Lab B209
5516 Nicholson Lane
Kensington, MD 20895
Telephone 301 435 4988
Karen Campbell

Page Last Updated: 07/15/2012
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English